Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
01 Fevereiro 2024 - 6:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2024
Commission File Number: 001-41661
JIN MEDICAL INTERNATIONAL LTD.
(Exact name of registrant as specified in its charter)
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of Principal Executive Office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Submission of Matters to a Vote of Security Holders.
At the extraordinary general meeting (the “EGM”)
of shareholders of Jin Medical International Ltd. (the “Company”) held at 9.30 a.m. Beijing Time on January 30,
2024 (January 29, 2024, at 8.30 p.m., Eastern Time), the Company’s shareholders voted on the matters described below.
Shareholders holding 6,234,204 ordinary shares of the Company were present in person or by proxy at the EGM, representing approximately
79.65% of the total 7,827,355 outstanding ordinary shares as of the record date of January 12, 2024, and therefore the Company has met
the quorum requirement for its EGM, which is more than one-third of the shares outstanding and entitled to vote at the EGM as of the record
date.
| 1. |
The Company’s shareholders voted to approve to by way of an ordinary resolution, with effect from the date as determined by any director of the Company, being no later than March 31, 2024, to subdivide each of the issued and unissued ordinary shares with a par value of US$0.001 each in the capital of the Company into twenty (20) ordinary shares with a par value of US$0.00005 each (the “Subdivision”), such that, following the Subdivision, the authorized share capital of the Company is US$50,000 divided into 1,000,000,000 shares with a par value of US$0.00005 each. The number of shares that voted for, against, and abstained from voting for this proposal is summarized in the table below: |
| Votes For | | |
Votes Against | | |
Votes Abstained | |
| | 6,234,204 | | |
| 118 | | |
| 0 | |
SIGNATURES
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
| |
JIN MEDICAL INTERNATIONAL LTD. |
| |
|
|
| Date: February 1, 2024 |
By: |
/s/ Erqi Wang |
| |
|
Erqi Wang |
| |
|
Chief Executive Officer |
2
Jin Medical (NASDAQ:ZJYL)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Jin Medical (NASDAQ:ZJYL)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
